Search
Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years
ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.
Read moreEHA - Access to Medicine
By reporting the unavailability of hematology medicine you are strengthening our efforts to improve patients' access to medicine across Europe. REPORT NOW
Read morePieter Sonneveld appointed Officer in the Order of Orange-Nassau
The EHA Board congratulates former EHA President Professor Pieter Sonneveld on his appointment as an Officer of the Order of Orange-Nassau by His Majesty King Willem-Alexander of the Netherlands.
Read moreMeet Maria-Victoria Mateos, our April Volunteer of the Month
Maria Victoria Mateos currently heads the Scientific Program Committee of the 24th EHA Congress which will be held on June 13-16 in Amsterdam.
Read moreMeet Maria-Victoria Mateos, our April Volunteer of the Month
Maria Victoria Mateos currently heads the Scientific Program Committee of the 24th EHA Congress which will be held on June 13-16 in Amsterdam.
Read moreMeet our Volunteers of the Month: Elizabeth, Francesca and Verena
Yes, you read that right. For this month, we have more than one Volunteer of the Month: Elizabeth Macintyre, Francesca Vinchi and Verena Gaidzik.
Read moreMeet our Volunteers of the Month: Elizabeth, Francesca and Verena
Yes, you read that right. For this month, we have more than one Volunteer of the Month: Elizabeth Macintyre, Francesca Vinchi and Verena Gaidzik.
Read morePRESS RELEASE: The future of research in hematology is here
“For the first time, hematologists in Europe came together to develop a roadmap to guide hematology research in Europe” says Professor Andreas Engert, chair of the EHA Research Roadmap Task Force, “Hematology in Europe has achieved a lot, but the discipline must focus and…
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- »